AIM ImmunoTech reports positive Phase 2 topline results for Ampligen in post-COVID fatigue

AIM ImmunoTech Inc.

Primary endpoint (PROMIS Fatigue Score at week 13) not significant; Ampligen showed lower fatigue at multiple timepoints vs placebo.
Secondary and ad hoc analyses showed differences in PROMIS Fatigue Score reaching or approaching statistical significance at several timepoints.
Six-Minute Walk Test: Ampligen group had higher distance traveled at week 13 vs placebo.
Safety: Ampligen generally well tolerated; no severe TEAEs or deaths. 15% mild treatment-related TEAEs in Ampligen group.
Study enrolled 80 subjects (40 per arm); 82.5% completed (90% Ampligen, 75% placebo).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.